Bluesky Facebook Reddit Email

Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase ™

02.06.01 | Noonan/Russo Communications

Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

February 4-8, 2001
Sheraton Hotel and Towers, Chicago, IL
Visit us at Posters #332 and 333 (Feb 6th)

For more information Contact:
Renee Connolly of Noonan/Russo Communications, Inc., 212-696-4455 ext 227,
r.connolly@noonanrusso.com
or
Michael Partridge of Vertex Pharmaceuticals, Incorporated, 617-577-6108
michael_partridge@vpharm.com

Keywords

Hiv Infections Medical Treatments Protease Inhibitors

How to Cite This Article

APA:
Noonan/Russo Communications. (2001, February 6). Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase ™. Brightsurf News. https://www.brightsurf.com/news/1EKXY071/clinical-advances-towards-the-simplification-if-hiv-therapy-first-once-daily-dosing-results-for-the-hiv-protease-inhibitor-agenerase.html
MLA:
"Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase ™." Brightsurf News, Feb. 6 2001, https://www.brightsurf.com/news/1EKXY071/clinical-advances-towards-the-simplification-if-hiv-therapy-first-once-daily-dosing-results-for-the-hiv-protease-inhibitor-agenerase.html.